Cellution Biologics Inc. Announces First Peer-Reviewed Publication Demonstrating Positive Outcomes for AmchoPlast™ in the Treatment of Chronic Diabetic Foot UlcersROSWELL, Ga., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellution Biologics, Inc., a leader in regenerative allograft solutions, proudly announces the publication of its first peer-reviewed clinical article, “Bridging the Wound Gap: Interim Results from Randomized Trials Evaluating Dehydrated Human Amnion-Intermediate Layer-Chorion Membrane for the Treatment of Non-healing Diabetic Foot Ulcers,” published in Cureus. This milestone marks a significant achievement for the company and reinforces its commitment to advancing evidence-based medicine.
Cellution Biologics Inc. Announces U.S. Launch of AmnioPlast 1 and AmnioPlast Double for Ocular Surface RepairROSWELL, Ga., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellution Biologics Inc., today announced the introduction of AmnioPlast 1™ (Dehydrated Monolayered Human Amnion Membrane Allograft) and AmnioPlast Double™ (Dehydrated, Dual-Layer Amnion Membrane Allograft), intended for use as a cover or barrier applied to the ocular surface following repair or reconstruction procedures of ocular disease and/or abnormalities.
